Search Result

Search Result

Results for "

C5a Inhibitors

" in MCE Product Catalog:

By Targets:	Complement System (9) Reactive Oxygen Species (1) SARS-CoV (2)
By Research Areas:	Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (7)

10

Inhibitors & Agonists

1

Peptides

2

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas

W-54011 4 Publications Verification	Complement System Reactive Oxygen Species	Inflammation/Immunology
W-54011 is a potent and orally active non-peptide C5a receptor antagonist. W-54011 inhibits the binding of ¹²⁵I-labeled *C5a* to human neutrophils with a K_i value of 2.2 nM. W-54011 also inhibits *C5a*-induced intracellular Ca²⁺ mobilization, chemotaxis, and generation of ROS in human neutrophils with IC₅₀s of 3.1 nM, 2.7 nM, and 1.6 nM, respectively.

Avacincaptad pegol sodium ARC1905	Complement System	Others
Avacincaptad pegol (ARC1905) is an anti-C5 RNA aptamer that inhibits the cleavage of complement factor 5 (C5) into C5a and C5b. Avacincaptad pegol is being used for the study of age-related macular degeneration (AMD).

Eculizumab Anti-Human C5, Humanized Antibody	Complement System	Cardiovascular Disease
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.

L-156602 Antibiotic L 156602; PD 124966	Complement System	Inflammation/Immunology
L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH).

C5aR-IN-1	Complement System	Inflammation/Immunology
C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).

C5aR-IN-3	Complement System	Inflammation/Immunology
C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).

C5aR-IN-2	Complement System	Inflammation/Immunology
C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49).

JPE-1375	Complement System	Inflammation/Immunology
JPE-1375 is a *complement C5a* receptor 1 (C5aR1*) antagonist. JPE-1375 effectively inhibits* polymorphonuclear leukocyte mobilization (EC₅₀=6.9 µM) and reduces TNF levels (EC₅₀=4.5 µM) in mice. JPE-1375 can be used in studies of autoimmune and inflammatory diseases.

SARS-CoV-2 3CLpro-IN-19	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC₅₀s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC₅₀ values between 30-69 nM.

Cat. No.	Product Name	Target	Research Area

C5aR1 antagonist peptide	Peptides	Others
C5aR1 antagonist peptide is a biological active peptide. (This linear peptide is derived from the C-terminus of the chemokine, complement fragment 5 anaphylatoxin (C5a). This peptide functions to inhibit C5a binding and function at human and rat C5a receptors. C5a is crucial to triggering cellular immune responses and its overexpression is involved in arthritis, Alzheimer’s disease, cystic fibrosis, systemic lupus erythematosus, and other immunoinflammatory diseases.)

Cat. No.	Product Name	Target	Research Area

Eculizumab Anti-Human C5, Humanized Antibody	Complement System	Cardiovascular Disease
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.

Vilobelimab CaCP-29, IFX-1	Complement System SARS-CoV	Infection Inflammation/Immunology
Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.

MCE Magic Cece

MedChemExpress: Contact Us; About Us; Headquarters; Distributors; Statement on False Report; Careers

Customer Support: Technical Support; Service; Ordering Information; Easy Return; Shipping Rates & Policies; Intellectual Property Promise

Resources: Free Sample; Resources; Molarity Calculator; Dilution Calculator; Terms & Conditions; Reconstitution Calculator; Specific Activity Calculator

Subscribe to our E-newsletter

Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.

Copyright © 2013-2023 MedChemExpress. All Rights Reserved.: Site Map Privacy Policy

Join with us